Literature DB >> 696441

The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium.

F Heppner, J R Möse.   

Abstract

Vascular glioblastomas become liquefied when contaminated with spores of the non-pathogenic Clostridium butyricum M 55. The spores are administered by intracarotid injection. The oncolysis is complete one week after injection. The glioblastoma is converted into a brain abscess which is then operated on appropriately. Forty nine patients have been treated in this manner. The rate of recurrence, however, remained uninfluenced.

Entities:  

Mesh:

Year:  1978        PMID: 696441     DOI: 10.1007/BF01406639

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  5 in total

1.  [The effect of non-pathogenic Clostridia on malignant tumors].

Authors:  A Propst; J R Möse
Journal:  Z Krebsforsch       Date:  1966

2.  [Oncolysis of malignant gliomas through apathogenic clostridia (strain "M 55")].

Authors:  F Heppner; J R Möse
Journal:  Zentralbl Neurochir       Date:  1966

3.  [Treatment of malignant tumors using spores of Clostridium butyricum M 55. I. Basic principles and development of the influencing of malignant tumors by microorganisms].

Authors:  H Kretschmer
Journal:  Arch Geschwulstforsch       Date:  1972

4.  [Oncolysis of malignant tumors by Clostridium strain M 55].

Authors:  J R Möse; G Möse; A Propst; F Heppner
Journal:  Med Klin       Date:  1967-02-03

5.  [Therapy of advanced malignant brain tumors].

Authors:  F Heppner
Journal:  Wien Klin Wochenschr       Date:  1966-07-01       Impact factor: 1.704

  5 in total
  22 in total

Review 1.  Tumour-targeting bacteria engineered to fight cancer.

Authors:  Shibin Zhou; Claudia Gravekamp; David Bermudes; Ke Liu
Journal:  Nat Rev Cancer       Date:  2018-12       Impact factor: 60.716

2.  Bacteria as tumor therapeutics?

Authors:  Tobias A Oelschlaeger
Journal:  Bioeng Bugs       Date:  2010-01-15

3.  Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy.

Authors:  Michelle Cronin; Fabrice Le Boeuf; Carola Murphy; Dominic G Roy; Theresa Falls; John C Bell; Mark Tangney
Journal:  Mol Ther       Date:  2014-02-26       Impact factor: 11.454

Review 4.  Immunobiologic aspects of the brain and human gliomas. A review.

Authors:  C J Wikstrand; D D Bigner
Journal:  Am J Pathol       Date:  1980-02       Impact factor: 4.307

5.  Bacteriolytic therapy of experimental pancreatic carcinoma.

Authors:  Claudia Maletzki; Michael Gock; Ulrike Klier; Ernst Klar; Michael Linnebacher
Journal:  World J Gastroenterol       Date:  2010-07-28       Impact factor: 5.742

Review 6.  Bacteria as vectors for gene therapy of cancer.

Authors:  Chwanrow K Baban; Michelle Cronin; Deirdre O'Hanlon; Gerald C O'Sullivan; Mark Tangney
Journal:  Bioeng Bugs       Date:  2010 Nov-Dec

Review 7.  Microbial-based therapy of cancer: current progress and future prospects.

Authors:  Nuno Bernardes; Raquel Seruca; Ananda M Chakrabarty; Arsenio M Fialho
Journal:  Bioeng Bugs       Date:  2009-12-02

8.  A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer.

Authors:  Zhiyu Li; John Fallon; John Mandeli; James Wetmur; Savio L C Woo
Journal:  J Natl Cancer Inst       Date:  2008-09-23       Impact factor: 13.506

9.  Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.

Authors:  Shie-Chau Liu; G-One Ahn; Mitomu Kioi; Mary-Jo Dorie; Adam V Patterson; J Martin Brown
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

10.  Bacteriolytic therapy can generate a potent immune response against experimental tumors.

Authors:  Nishant Agrawal; Chetan Bettegowda; Ian Cheong; Jean-Francois Geschwind; Charles G Drake; Edward L Hipkiss; Mitsuaki Tatsumi; Long H Dang; Luis A Diaz; Martin Pomper; Mohammad Abusedera; Richard L Wahl; Kenneth W Kinzler; Shibin Zhou; David L Huso; Bert Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.